Atrium Therapeutics announced it granted equity awards to eight newly hired non-executive employees as a material inducement to their employment. The awards, made under the company's 2026 Employment Inducement Incentive Award Plan, consist of non-qualified stock options to purchase an aggregate of 66,000 shares of common stock at an exercise price of $12.66 per share, and restricted stock units covering an aggregate of 33,000 shares. Both the options and restricted stock units vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over 36 months for the options and annually over three years for the restricted stock units, subject to continued service. The grants were approved by the Human Capital Management Committee of the board of directors and were made outside the company's stockholder-approved equity plans in accordance with Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics, Inc. Common StockEquity grants to new hires are a routine capital event; no direct impact on company performance.